RxDoctor Payments Data

Stephanie Casteel

Family · Redding, CANPI 1326610452

Payments from drug & device makers

$1,814in general payments, 2019–2025

Across 77 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$380
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$310
  • GSK$284
  • Novo Nordisk$173
  • Zynex Medical, Inc.$156
  • Boehringer Ingelheim$154
  • plus $358 from 7 others

What the payments were for

  • Food & beverage$1,814100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,814 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$126,386
Medicare patients
399
Services billed
1,495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide119$122,294
JardianceEmpagliflozin49$60,926
FarxigaDapagliflozin Propanediol35$50,381
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$44,952
EliquisApixaban35$40,401
TrulicityDulaglutide40$39,519
VraylarCariprazine Hcl18$25,501
OzempicSemaglutide24$23,959
XareltoRivaroxaban15$23,621
Celecoxib39$4,102
Gabapentin104$3,294
Albuterol Sulfate HfaAlbuterol Sulfate93$3,063
Levothyroxine Sodium180$2,404
SynthroidLevothyroxine Sodium25$1,697
Ventolin HfaAlbuterol Sulfate18$1,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$380$161,812159 claims
Boehringer IngelheimJardiance$154$60,92649 claims
AstraZenecaFarxiga$19$50,38135 claims
GSKTrelegy Ellipta$284$44,95231 claims
AbbVieVraylar, Synthroid$62$27,19943 claims
Novo NordiskOzempic$173$23,95924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.

Other family in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →